PL2214693T3 - Zastosowanie melanokortyn do leczenia insulinowrażliwości - Google Patents

Zastosowanie melanokortyn do leczenia insulinowrażliwości

Info

Publication number
PL2214693T3
PL2214693T3 PL08846334T PL08846334T PL2214693T3 PL 2214693 T3 PL2214693 T3 PL 2214693T3 PL 08846334 T PL08846334 T PL 08846334T PL 08846334 T PL08846334 T PL 08846334T PL 2214693 T3 PL2214693 T3 PL 2214693T3
Authority
PL
Poland
Prior art keywords
melanocortins
insulin sensitivity
treat insulin
treat
sensitivity
Prior art date
Application number
PL08846334T
Other languages
English (en)
Polish (pl)
Inventor
Heather A Halem
Michael Dewitt Culler
Andrew A Butler
Original Assignee
Ipsen Pharma Sas
Board Of Supervisors Of Louisiana State Univ And Agriculture And Mechanical College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma Sas, Board Of Supervisors Of Louisiana State Univ And Agriculture And Mechanical College filed Critical Ipsen Pharma Sas
Publication of PL2214693T3 publication Critical patent/PL2214693T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL08846334T 2007-11-05 2008-11-05 Zastosowanie melanokortyn do leczenia insulinowrażliwości PL2214693T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US193307P 2007-11-05 2007-11-05
EP08846334.4A EP2214693B1 (fr) 2007-11-05 2008-11-05 Utilisation de mélanocortines pour traiter une sensibilité à l'insuline
PCT/US2008/012490 WO2009061411A2 (fr) 2007-11-05 2008-11-05 Utilisation de mélanocortines pour traiter une sensibilité à l'insuline

Publications (1)

Publication Number Publication Date
PL2214693T3 true PL2214693T3 (pl) 2016-03-31

Family

ID=40626385

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08846334T PL2214693T3 (pl) 2007-11-05 2008-11-05 Zastosowanie melanokortyn do leczenia insulinowrażliwości

Country Status (20)

Country Link
US (6) US9155777B2 (fr)
EP (2) EP2979703B1 (fr)
JP (3) JP2011502987A (fr)
KR (3) KR20150013339A (fr)
CN (2) CN103316345B (fr)
AR (1) AR069461A1 (fr)
AU (1) AU2008325194B2 (fr)
BR (1) BRPI0819188B1 (fr)
CA (2) CA2952095C (fr)
DK (1) DK2214693T3 (fr)
ES (2) ES2690556T3 (fr)
HU (1) HUE026842T2 (fr)
IL (2) IL205554A (fr)
NZ (1) NZ585131A (fr)
PL (1) PL2214693T3 (fr)
PT (2) PT2979703T (fr)
RU (1) RU2453328C2 (fr)
TR (1) TR201815292T4 (fr)
TW (1) TWI374030B (fr)
WO (1) WO2009061411A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2618315T3 (es) * 2007-05-25 2017-06-21 Ipsen Pharma S.A.S. Ligandos del receptor de melanocortina modificados con hidantoína
NZ585131A (en) 2007-11-05 2012-10-26 Ipsen Pharma Sas Use melanocortins to treat insulin sensitivity
KR101726893B1 (ko) 2009-06-08 2017-04-13 팔라틴 테크놀로지스 인코포레이티드 멜라노코르틴 수용체-특이적 펩티드
WO2010144341A2 (fr) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Peptides spécifiques des récepteurs aux mélanocortines à pont lactame
BR112012002445A2 (pt) * 2009-08-05 2015-10-13 Ipsen Pharma Sas uso de um agonista do receptor 4 de melanocortina.
CN102574894A (zh) * 2009-08-31 2012-07-11 张力控制股份有限公司 稳定化的黑皮质素配体
US9314509B2 (en) 2009-11-16 2016-04-19 Ipsen Pharma S.A.S. Pharmaceutical compositions of melanocortin receptor ligands
JP2013511554A (ja) 2009-11-23 2013-04-04 パラティン テクノロジーズ，インコーポレイテッド メラノコルチン−１受容体特異的線状ペプチド
WO2011063366A1 (fr) 2009-11-23 2011-05-26 Palatin Technologies, Inc. Peptides cycliques spécifiques du récepteur de la mélanocortine-1
CA2833676C (fr) * 2011-06-14 2019-04-23 Ipsen Pharma S.A.S. Composition a liberation prolongee contenant des peptides en tant que principes actifs
CA2862444A1 (fr) 2011-12-29 2013-07-04 Rhythm Metabolic, Inc. Methode de traitement de troubles associes au recepteur 4 de la melanocortine dans des porteurs heterozygotes
EP2814501A4 (fr) 2012-03-13 2016-03-02 Tensive Controls Inc Analogues de mélanocortine présentant une activité et un transport améliorés
RU2020120797A (ru) 2013-03-15 2020-07-02 Ритм Фармасьютикалз, Инк. Пептидные композиции
PL2970389T3 (pl) 2013-03-15 2021-03-08 Rhythm Pharmaceuticals, Inc. Kompozycje farmaceutyczne
WO2016130966A1 (fr) * 2015-02-13 2016-08-18 University Of Virginia Patent Foundation Compositions et procédés de régulation de la pression sanguine
US11331375B2 (en) 2015-07-29 2022-05-17 University Of Virginia Patent Foundation Compositions and methods for regulating leukocyte adhesion
WO2017049140A2 (fr) 2015-09-18 2017-03-23 Wake Forest University Health Sciences Analogues d'angiotensine (1-7) et procédés associés
US11124541B2 (en) * 2016-10-18 2021-09-21 Regents Of The University Of Minnesota Chimeric melanocortin ligands and methods of use thereof
US11763106B2 (en) 2018-06-05 2023-09-19 The Research Foundation For The State University Of New York Method for passive wireless channel estimation in radio frequency network and apparatus for same
US11332499B2 (en) 2018-08-16 2022-05-17 Regents Of The University Of Minnesota Cyclic peptides and methods of use thereof
EP4618952A2 (fr) * 2022-11-18 2025-09-24 Rhythm Pharmaceuticals, Inc. Méthodes de traitement de l'obésité avec un agoniste du mc4r
WO2025151135A1 (fr) * 2024-01-08 2025-07-17 Endevica Bio, Inc. Méthodes de traitement du cancer et/ou d'états pathologiques liés à la chimiothérapie à l'aide d'analogues de mélanocortine d'origine non naturelle

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5665702A (en) 1995-06-06 1997-09-09 Biomeasure Incorporated Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US5916883A (en) 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
EP1322954A4 (fr) * 2000-09-13 2005-08-03 Eleanor Roosevelt Inst Procede de traitement de la resistance a l'insuline dans l'obesite et le diabete
WO2003099818A1 (fr) * 2002-05-23 2003-12-04 Chiron Corporation Composes de quinazolinone substitues
EP1460070B1 (fr) 2003-03-20 2007-05-16 Santhera Pharmaceuticals (Schweiz) AG Dérivés substitués de la pipéridine et la pipérazine comme modulateurs du récepteur de la melanocortine-4
CA2519939A1 (fr) 2003-03-26 2004-10-14 Merck & Co., Inc. Derives de piperidine bicycliques utilises comme agonistes du recepteur 4 de la melanocortine
CN1784423A (zh) * 2003-05-09 2006-06-07 诺沃挪第克公司 用于治疗肥胖的肽
BRPI0409976A (pt) 2003-05-09 2006-05-09 Novo Nordisk As composto, métodos para retardar a progressão de igt diabetes do tipo 2, para retardar a progressão de diabetes do tipo 2 para diabetes que requer insulina, para tratar obesidade ou prevenir excesso de peso para regular o apetite para induzir saciedade, para prevenir ganho de peso após se ter tido sucesso em perder peso, para aumentar dispêndio de energia, para tratar uma doença ou estado e para tratar bulimia, composição farmacêutica, e, uso de um composto
KR20060026011A (ko) * 2003-05-09 2006-03-22 노보 노르디스크 에이/에스 비만 치료용 펩티드
CA2530024A1 (fr) * 2003-06-19 2005-01-06 Eli Lilly And Company Agonistes du recepteur 4 de la melanocortine (mc4) et utilisations
US20070123453A1 (en) * 2004-03-29 2007-05-31 Heiman Mark L Uses of melanocortin-4 receptor (mc4r) agonist peptides administered by continuous infusion
US20080200376A1 (en) * 2004-10-29 2008-08-21 Maccoss Malcolm Compositions and Methods For the Treatment Of Obesity and Sexual Dysfunction
PL2286825T3 (pl) * 2005-07-08 2017-06-30 Ipsen Pharma Ligandy receptora melanokortyny
JP2009500426A (ja) 2005-07-08 2009-01-08 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス メラノコルチン受容体のリガンド
CN101370488B (zh) 2005-11-22 2012-07-18 奥雷西根治疗公司 增加胰岛素敏感性的组合物
ES2618315T3 (es) * 2007-05-25 2017-06-21 Ipsen Pharma S.A.S. Ligandos del receptor de melanocortina modificados con hidantoína
AR066175A1 (es) * 2007-06-15 2009-08-05 Sod Conseils Rech Applic Ligandos del receptor de melanocortina de peptidos ciclicos
NZ585131A (en) * 2007-11-05 2012-10-26 Ipsen Pharma Sas Use melanocortins to treat insulin sensitivity
BR112012002445A2 (pt) 2009-08-05 2015-10-13 Ipsen Pharma Sas uso de um agonista do receptor 4 de melanocortina.

Also Published As

Publication number Publication date
EP2979703A1 (fr) 2016-02-03
TWI374030B (en) 2012-10-11
BRPI0819188B1 (pt) 2021-06-22
EP2214693B1 (fr) 2015-09-09
KR20130065725A (ko) 2013-06-19
WO2009061411A2 (fr) 2009-05-14
IL205554A (en) 2017-01-31
CA2952095C (fr) 2020-02-18
DK2214693T3 (en) 2015-11-30
US20150366934A1 (en) 2015-12-24
JP2013144690A (ja) 2013-07-25
HUE026842T2 (en) 2016-08-29
AU2008325194B2 (en) 2012-04-19
JP2011502987A (ja) 2011-01-27
PT2214693E (pt) 2015-12-07
NZ585131A (en) 2012-10-26
PT2979703T (pt) 2018-10-31
BRPI0819188A2 (pt) 2015-09-01
IL249998B (en) 2018-07-31
RU2453328C2 (ru) 2012-06-20
HK1184692A1 (zh) 2014-01-30
WO2009061411A3 (fr) 2010-04-15
KR101290623B1 (ko) 2013-08-07
US20180303899A1 (en) 2018-10-25
US9827286B2 (en) 2017-11-28
KR101662044B1 (ko) 2016-10-04
KR20100075680A (ko) 2010-07-02
TR201815292T4 (tr) 2018-11-21
US20100311647A1 (en) 2010-12-09
AR069461A1 (es) 2010-01-27
US9155777B2 (en) 2015-10-13
JP5964767B2 (ja) 2016-08-03
JP2015131827A (ja) 2015-07-23
EP2214693A4 (fr) 2012-04-11
HK1146242A1 (en) 2011-05-27
AU2008325194A1 (en) 2009-05-14
EP2214693A2 (fr) 2010-08-11
US20190111105A1 (en) 2019-04-18
CA2704651A1 (fr) 2009-05-14
IL249998A0 (en) 2017-03-30
US9439943B2 (en) 2016-09-13
CN103316345A (zh) 2013-09-25
TW200932258A (en) 2009-08-01
CA2952095A1 (fr) 2009-05-14
EP2979703B1 (fr) 2018-07-18
HK1221147A1 (en) 2017-05-26
CA2704651C (fr) 2017-03-07
IL205554A0 (en) 2010-12-30
US20220339239A1 (en) 2022-10-27
ES2690556T3 (es) 2018-11-21
ES2555522T3 (es) 2016-01-04
CN101980717A (zh) 2011-02-23
US20160354429A1 (en) 2016-12-08
RU2010122897A (ru) 2011-12-20
CN103316345B (zh) 2016-05-18
KR20150013339A (ko) 2015-02-04

Similar Documents

Publication Publication Date Title
PT2214693E (pt) Utilização de melanocortinas para tratar a sensibilidade à insulina
ZA201104467B (en) Heterocyclic compounds and methods of use
IL213547A0 (en) Compounds and methods of use
ZA201006648B (en) Methods of treatment
IL207292A0 (en) Use of ranolazine for treating pain
NO2016023I1 (no) Glycerol fenylbutyrat
EP2480081A4 (fr) Composés hétérocycliques pontés et leurs méthodes d'utilisation
ME03508B (fr) Polythérapie pour le traitement du diabète
GB0707750D0 (en) Treatment of organic matter
HRP20181877T1 (hr) Postupci za liječenje lijekovima koji uklanjaju amonijak
IL217966A0 (en) Hsl inhibitors useful in the treatment of diabetes
ZA200901452B (en) Treatment of vertigo with acetyl-L-leucine
PL2148676T3 (pl) Stosowanie sapacytabiny do leczenia choroby proliferacyjnej
GB201211237D0 (en) CDK5 inhibitors and therapeutic uses thereof
GB2448592B (en) Improvements to coffins
GB0723100D0 (en) Treatment of HFnEF
ZA201100163B (en) Unit dosage of apadenoson
GB0814296D0 (en) Improvements to coffins
EP2066171A4 (fr) Administration d'une substance de traitement à des éléments poreux
PL2346485T3 (pl) Stosowanie betainy
GB0802903D0 (en) Treatment of diabetes
GB0801958D0 (en) Improvements relating to electro-optical sensors and their use
IL190834A0 (en) Improvements to bandages
GB0816217D0 (en) Treatment of hepatitis C
HU0800656D0 (en) Effective use of tea-composition